There is currently a new experimental therapy test for Parkinson's disease that involves spraying millions of special cell cells to brain patients with a clinical trial condition.
The study, which began in October, is carried out by researchers at Kyoto University in Japan. So far, researchers have begun to handle one man in their 50s, according to AFP.
Although previous studies have experienced Parkinson's stem cell therapies, the new study is the first to use multi-cell cell cells offered in this way, or iPSCs. These are "adult" cells (such as blood cells or skin cells, rather than embryonic cells) that have been redesigned so that they are similar to cells in the early development, and have the potential to form any type of cells in the body.
For the study, the investigators used iPSCs to create "progenitor dopaminergic" cells, or cells that cause cell cells that produce dopamine, brain chemistry needed to control muscle movement. In patients with Parkinson's disease, the cells of the brain that produce dopamine die, resulting in symptoms such as roaming and difficulty with walking, moving and co-ordination. [10 Things You Didn’t Know About the Brain]
In the new trial, researchers hope to show that these transplant stem cells will help replace cells that produce dopamine and restore and restore dopamine production, according to the Michael J Foundation Fox.
For the treatment, the researchers sprayed 2.4 million cell cells to the left side of the man's brain, in an operation that took 3 hours, according to AFP. The patient will now be monitored for side effects, and if there are no problems, the researchers will spray another 2.4 million stem cell to the right of the brain.
The researchers intend to register a total of seven patients in the trial and to trace patients for two years.
The iPSCs resulted from donors, so patients will need to take drugs to stop their immune system to prevent the refusal of transplant cells, according to Kyoto University.
Originally published on Living Science.